CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

  • Moore, Maggie (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date8/10/24 → 8/10/26

Keywords

  • clinical trial
  • Estrogen Receptor
  • Breast Cancer
  • Camizestrant
  • endocrine therapy